The Future of Diabetes Care: Empowering the Consumer

Diabetes care has reached epidemic prevalence in the United States, with over 37 million diagnosed patients, 96 million people exhibiting pre-diabetes symptoms, and the total direct annual cost to the US Healthcare system at $237bn, according to the Center for Disease Control. We convene industry leaders working at the forefront of diabetes clinical and digital solutions that may unlock a new future of diabetes care. New technology is going direct to consumers, empowering patients, and reducing industry costs.

Watch the Panel Discussion

A Discussion with Industry-Experts

Betul Hatipoglu, MD, Director of Diabetes and Obesity Center at University Hospitals: Dr. Hatipoglu practices as an endocrinologist and currently holds many roles — Professor of Medicine at Case Western Reserve University School of Medicine, Vice Chair at University Hospitals System Clinical Affairs, Medical Director of the Diabetes & Obesity Center, and the Mary B. Lee Chair in Adult Endocrinology at the University Hospitals Cleveland Medical Center.

Olivia Chung, Digital Health Innovation Lead US at Roche: Olivia worked in health insurance on value-based and virtual care in the early days of developing these new approaches to patient experience, even establishing a chief experience officer position. In addition, Olivia has been a practicing certified dietitian for over 20 years, specializing in cardiac, diabetes management, and other chronic conditions.

Diabetes Webinar_Fireside Chat Headshots Graphic

The Highlights of the Panel Discussion

  • While new consumer continuous glucose monitoring (CGM) solutions exist, they are not widely used for pre-diabetic patients and patients, not on insulin therapy but already diagnosed with type two diabetes. More research will determine the clinical use cases for early CGM implementation.
  • New solutions, particularly continuous glucose monitoring and digital solutions available in different languages, are breaking barriers. Previously, patients experienced diabetes as a silent disease with little insight into the damage being done to the body. In addition, the care needed to be enabled in a culturally competent manner.
  • The next breakthrough is artificial intelligence predicting the need for insulin and suggesting food intake and lifestyle adjustments. A further promising development is the iLet bionic pancreas, which is awaiting FDA approval and undergoing a pivotal trial to deliver insulin autonomously and mimic a naturally healthy pancreas.
  • Recently released federal social determinants of health guidelines are going to help with regulation on how providers and payers have to respond to chronic illnesses. They may need to increase data collection to inform better health outcomes.

Reshape the Future of Healthcare

We connect the best startups in the world to corporations who want to disrupt the healthcare industry. 

We focus on digital health technologies that challenge clinical practices, improve data analytics, and enhance the patient journey across the continuum of care.